For example, the efficacy of the adjunctive use of brexpiprazole, an antipsychotic drug with a potent affinity and partial agonist activity at 5‐HT1A receptors [63], may be applicable to cognitive impairment in schizophrenia, MDD, and bipolar depression [64, 65, 66]. This evidence concerns the gene HTR1A and major depressive disorder.